SW-682 in Advanced Solid Tumors

This early-phase study tests a new drug called SW-682 in people with advanced solid tumors that have specific changes in a pathway called the Hippo signaling pathway, which controls how cells grow. Tumors targeted include mesothelioma (a rare cancer of the lining of the lungs or abdomen) and other solid tumors with NF2, FAT1, LATS1/2, or YAP gene mutations. **You may be eligible if...** - You have an advanced or metastatic solid cancer that has not responded to or is not suitable for standard treatments - You have mesothelioma (with or without NF2 mutations), OR you have a solid tumor with NF2 or other Hippo pathway mutations/fusions - You are able to tolerate further treatment **You may NOT be eligible if...** - Your cancer does not have one of the specific Hippo pathway alterations - You have not yet tried available standard treatments - You have significant organ impairment or active infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.